Abstract. Graves 
Graves' disease is thought to be an autoimmune disease in which antibodies against the TSH recep¬ tor stimulate thyroid function (McKenzie 1980; Burman & Baker 1985) . Antithyroid drug therapy has been carried out with thioureylenes for more than 40 years in patients with Graves' thyrotoxicosis (Astwood 1944) (Table 9 ). It is obvious that the percentage of hyperthy¬ roidism relapse increases with patient age (Fig. 2) . This may be due to the development of autono¬ mously functioning nodules, which might exist even in Graves' goitres and would be especially prevalent in the iodine-deficient area of Germany (Studer 1986 (Studer 1986 We therefore think a prediction parameter should have a high sensitivity (of at least 0.90) in order to reduce the probability of wrongly stop¬ ping therapy. A lower specificity (at least of 0.70) on the other hand seems acceptable, since it only in¬ creases the probability of wrongly continuing drug treatment.
TSH receptor antibodies have most frequently been investigated as a parameter for clinical pre¬ diction in Graves' disease. These antibodies stimu¬ late thyroid function, and thus their detection was thought to be a good parameter (Burman & Baker 1985) . This hypothesis seemed to be confirmed in studies by Davies et al. (1977) (Smith et al. 1988) , it was speculated that our TBIab assay using thyroid membrane fragments is less sensitive and specific than the methods applied by other groups (Wilson et al. 1985 (Wilson et al. , 1986 (Irvine et al. 1977) and that this development is often accompanied by a rise of microsomal and/or thyroglobulin anti¬ bodies (Wood & Ingbar 1979; Lamberg et al. 1981; Hirota et al. 1986 ). In contrast to these studies, re¬ sults were published to the effect that high titres of Mc-ab (Hamada et al. 1987) or Tg-ab (Meng et al. 1981 ) indicate a relapse of hyperthyroidism after drug withdrawal. In our study, we could not find a significantly different reiapse rate for patients with high and low antibody titres at any given time dur¬ ing therapy, nor were we able to achieve sufficient reliability for an individual prognosis by measur¬ ing antibody titres. The follow-up time in this study, however, was too short for a development of immune thyroiditis (Lamberg et al. 1981) (Bogner et al. 1987) (Endo et al. 1978; Schleusener et al. 1978) .
It is well known that Caucasians with Graves' disease show a relatively high prevalence of HLA antigens B8 and DR3 (Grumet et al. 1974; Farid 1981; Dahlberg et al. 1981) . HLA-typing of 253 pa¬ tients in this study yielded a prevalence of 34% HLA-B8 and 39% HLA-DR3 in patients with Graves' disease, which is significantly elevated compared with normals. We previously found a prevalence of 18% HLA-B8 and 20% HLA-DR3 in normal Caucasians in our region (Schleusener et al. 1983 ). In patients with Graves' disease prevalen¬ ces of 44-53% HLA-B8 (Allanic et al. 1980; Dahlberg et al. 1981) and 64% (Farid 1981) (Gutekunst et al. 1986 ). Autonomously functioning areas are thought to develop in some of these enlarged thyroids (Gerber et al. 1983 ), possibly even in Graves' goitres (Studer 1986 (Meng et al. 1982) (Wall et al. 1981; Jacobson & Gorman 1984) .
The fact that the course of Graves' disease can¬ not be reliably predicted may be explained by the complex mechanism involved: many factors can in¬ fluence the development of an autoimmune dis¬ ease (Wick 1987 
